Sign in →

Test ID SEQB Sequential Maternal Screening, Part 2, Serum


Advisory Information


Do not order this test unless test SEQA / Sequential Maternal Screening, Part 1, Serum has already been ordered.

 

If a standalone second-trimester screen is desired, order QUAD1 / Quad Screen (Second Trimester) Maternal, Serum.

 

If a stand-alone neural tube defect risk assessment is desired, order MAFP1 / Alpha-Fetoprotein (AFP), Single Marker Screen, Maternal, Serum.



Additional Testing Requirements


Sequential maternal screening is a 2-step test that includes a first-trimester sample (SEQA / Sequential Maternal Screening, Part 1, Serum) and a second-trimester sample (SEQB / Sequential Maternal Screening, Part 2, Serum).



Necessary Information


Collection date is required.



Specimen Required


Container/Tube:

Preferred: Red top

Acceptable: Serum gel

Submission Container/Tube: Plastic vial

Specimen Volume: 1 mL

Collection Instructions:

1. Collect blood between 15 weeks, 0 days and 22 weeks, 6 days. Do not collect blood after performing amniocentesis, as that may lead to an artificially increased serum alpha-fetoprotein level and unreliable results.

2. Centrifuge and aliquot within 2 hours of collection.


Useful For

Prenatal screening for Down syndrome, neural tube defects, and trisomy 18

 

Identifying abnormal levels of alpha-fetoprotein in the second trimester

Method Name

Immunoenzymatic Assay

Reporting Name

Sequential Maternal Screen, Part 2

Specimen Type

Serum

Specimen Minimum Volume

0.5 mL

Specimen Stability Information

Specimen Type Temperature Time Special Container
Serum Refrigerated (preferred) 7 days
  Frozen  90 days

Reference Values

An interpretive report will be provided.

Day(s) and Time(s) Performed

Monday through Friday; 8 a.m.-4:30 p.m.

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

CPT Code Information

81511

82105 (if appropriate)

82677 (if appropriate)

84702 (if appropriate)

86336 (if appropriate)

LOINC Code Information

Test ID Test Order Name Order LOINC Value
SEQB Sequential Maternal Screen, Part 2 48800-7

 

Result ID Test Result Name Result LOINC Value
29476 Recalculated Maternal Serum Screen 43995-0
601813 Results Summary 49092-0
29500 Down Syndrome Screen Risk Estimate 43995-0
29501 Down Syndrome Maternal Age Risk 49090-4
29502 Trisomy 18 Screen Risk Estimate 43994-3
602040 Neural Tube Defect Risk Estimate 49091-2
29491 NT 49035-9
601814 NT MoM 49035-9
29492 NT Twin 49035-9
601815 NT Twin MoM 49035-9
29887 PAPP-A 48407-1
601816 PAPP-A MoM 76348-2
29494 AFP 20450-3
601817 AFP MoM 23811-3
602805 AFP MoM (14,0-14,6) 23811-3
29495 uE3 20466-9
601818 uE3 MoM 21264-7
29496 hCG, Total 83086-9
601819 hCG, Total MoM 23841-0
29497 Inhibin 35738-4
601820 Inhibin MoM 36904-1
29503 Interpretation 49092-0
29505 Recommended Follow Up 80615-8
29504 Additional Comments 48767-8
29477 Specimen Collection Date 1 33882-2
29493 Specimen Collection Date 2 33882-2
29478 Maternal Date of Birth 21112-8
29892 Calculated age at EDD 43993-5
29479 Maternal Weight 29463-7
29481 Insulin Dependent Diabetes 33248-6
29482 Patient Race 32624-9
601811 Current cigarette smoking status 72166-2
29485 Scan Date 34970-4
29488 CRL 11957-8
29489 CRL Twin 11957-8
29893 GA on Collection by U/S Scan 1 11888-5
29894 GA on Collection by U/S Scan 2 11888-5
29886 Number of Fetuses 11878-6
29490 Chorions 92568-5
29888 IVF 47224-1
601808 Prev Down (T21) / Trisomy Pregnancy 53826-4
601809 Prev Pregnancy w/ Neural Tube Defects 53827-2
601807 Initial or repeat testing 89231-5
601810 Patient or father of baby has a NTD 53827-2
601803 Sonographer Name 49088-8
602041 Sonographer Code No LOINC Needed
601812 Sonographer Reviewer ID 49089-6
601804 Physician Phone Number 68340-9
29506 General Test Information 62364-5

NY State Approved

Yes